Monday, June 24, 2013
FDA's Janet Woodcock says the flood of breakthrough
therapy designations is probably not an anomaly and is a result of the
increased number of targeted therapies that present dramatic efficacy in early
Speaking on BioCentury This
Week television, Woodcock said many breakthroughs, especially in cancer,
could be stepping stones to the ultimate goal, durable remissions and cures
(see BioCentury This Week, June 23).